Lassen Therapeutics Secures $85 Million in Oversubscribed Series B Financing
Clinical-stage biotech company Lassen Therapeutics has successfully closed an oversubscribed Series B financing round, raising $85 million. Frazier Life Sciences co-led the financing alongside new investor Longitude Capital, with participation from BVF Partners, Catalio Capital Management, Alta Partners, and Longwood Capital. Lassen Therapeutics focuses on developing first-in-class antibody therapeutics, including LASN01 targeting interleukin-11 receptor for … Read more